We describe virilization in a newborn female secondary to bilateral congenital juvenile granulosa cell tumor (JGCT). The patient presented with abdominal mass and ambiguous genitalia at birth, and bilateral ovarian masses were discovered on further imaging. The patient underwent bilateral salpingooophorectomy in staged procedures, as it became apparent that we could not spare the ovaries. Diagnosis of JGCT was confirmed by surgical pathology. She required no adjuvant therapy and has no signs of recurrence at two-year follow-up.
Virilization and ambiguous genitalia in a newborn female is an uncommon and complex problem with many possible causes. The most common cause for virilization in genetically female infants is congenital adrenal hyperplasia (CAH). Other conditions in the differential diagnosis include exposure to maternal androgens or exogenous hormones. We present a case of virilization secondary to bilateral congenital juvenile granulosa cell tumor (JGCT) with no other associated abnormalities.
Case report
A 5.2-kilogram 37-week gestation female was born to a 42-yearold G5P2202 woman by Cesarean section for failure to progress. Pregnancy was complicated by polyhydramnios and pregnancyinduced hypertension. Ultrasound at 20 weeks was consistent with a normal female fetus. APGARs at birth were 8 and 9. On physical exam, she was noted to have a palpable abdominal mass and ambiguous genitalia. The mid-abdominal mass was firm, mobile, nontender, and 8e10 cm in diameter. She had clitoromegaly with normal labia majora without evidence of posterior labial fusion. Her urethral and vaginal orifices appeared normal, and she had a patent anus. Basic metabolic panel was normal. Ultrasound demonstrated an abdominal mass with a cystic component. MRI revealed a normal uterus and bilateral cystic masses of the ovaries. On MRI, the larger mass measured 7.4 cm Â 5.2 cm x 4.8 cm, and the smaller one measured 4.0 cm Â 2.5 cm Â 2.2 cm (Fig. 1) .
Diagnostic laparoscopy demonstrated a large mass in the midline originating from the left ovary, as well as a smaller mass originating from the right ovary that had undergone torsion. Examination of the left ovary demonstrated multiple small cysts with no discernible ovarian tissue distinct from the mass. The right ovary was not ischemic and was detorsed. Surgical exploration was expedited before return of any laboratory values because of concern for torsion. With the evidently bilateral nature of the pathology, biopsies were obtained of the larger left mass in hopes that any normal ovarian tissue would be able to be preserved.
Pathology demonstrated juvenile granulosa cell tumor (JGCT) with no residual normal ovary tissue. Hormonal studies are listed in Table 1 . On day ten of life, she underwent left salpingooophorectomy and right ovarian biopsy with peritoneal washings. It was impossible to dissect the left Fallopian tube free from the mass. Right ovary pathology demonstrated JGCT as well, but peritoneal fluid was negative for neoplastic cells. After consultation with oncology, we elected to continue observation with surgery at a later date, to allow the possibility of ovary-sparing surgery.
She was discharged from the hospital at 5 weeks of age. At follow-up, her clitoromegaly had slightly improved, and her right ovary was smaller at 4.2 Â 1.6 Â 1.7 cm on ultrasound. Her followup labs are shown in Table 1 . She was readmitted at 4.5 months with small bowel obstruction. She required adhesiolysis, and it was evident that her JGCT had not regressed. Right salpingooophorectomy was performed at this time. Pathology demonstrated very small fragments of ovary with multiple nodules and cystic areas of JGCT. Peritoneal washings were again negative. Therefore, the tumor had been limited to the bilateral ovaries, corresponding to FIGO stage Ib, for which no chemotherapy is indicated. By Children's Oncology Group (COG) staging, it would be stage II.
She was lost to follow-up after discharge for 2 years and seen again at the age of 2.5 years, fortunately without evidence of recurrence. Tumor markers were normal with Inhibin B less than 10 pg/mL and AMH less than 0.1 ng/mL, and ultrasound demonstrated no evidence of recurrent or residual tumor. She will continue long-term surveillance and will require hormone replacement therapy.
Discussion
Juvenile granulosa cell tumors (JGCT) are the most common sex cord-stromal tumor (SCST) in the pediatric population. Gynecologic tumors make up less than 5% of pediatric neoplasms, and SCSTs are rare within this group (10%), with germ cell tumors being far more common (60e70%). SCST most commonly presents between four and nine years of age and JGCT are exceedingly rare in infancy [1e4] .
In a 20-year series from Pakistan, the median age of presentation of JGCT was fourteen years, with only two occurring before one year of age [5] . Bouffet et al. had similar findings in a comprehensive review in 1997 [1] . Only 25 cases of JGCT in infants less than one year old have been documented [6, 7] . Bilateral ovarian JGCT occurs in about three percent of cases, but in infants, this tends to be associated with other congenital abnormalities (Ollier's disease, Maffucci's syndrome, leprechaunism) [2, 8] .
Typical presentation of JGCT is abdominal pain and distension, frequently associated with endocrine manifestations such as isosexual pseudoprecocity or virilization in the pre-menarchal population. Occasionally, JGCT may present with peritonitis from torsion or hemorrhagic shock secondary to tumor rupture. Work-up for endocrine disturbances and associated genetic abnormalities is indicated in these patients. Hormone levels should be obtained at baseline as tumor markers.
Once the diagnosis has been established, resection is the appropriate management, as these tumors are hormonally active and do have malignant potential. Ovarian preservation should be emphasized if possible. If normal ovary remains, the tumor should be resected preserving ovarian tissue, especially in the case of bilateral pathology. In this case, there was essentially no normal ovary remaining. Oophorectomy is sufficient in FIGO stage Ia or Ib, but in stage IIa-b, hysterectomy may be considered as well. In infants, surgery may be limited to resection of the cyst or tumor, if it is possible to spare the ovary, as the disease tends to be less aggressive in this age group. Peritoneal washings and biopsy of the contralateral ovary should always be performed [1, 2, 9] .
Chemotherapy is recommended only if the tumor has spread beyond the ovaries. It is uncommon for patients to present with advanced disease. In one study from 2002, seven patients were identified with tumors stage II or higher. Adjuvant cisplatin-based chemotherapy was used with all patients achieving complete clinical remission. Radiotherapy was used in one patient with diffuse peritoneal metastases [10] . Schneider et al., in 2005 described long-term survival and remission in four of six patients with stages II and III JGCT following surgery and adjuvant chemotherapy with cisplatin-based therapy. The two patients that died showed high proliferative activity of the malignant cells, while survivors had lower mitotic counts. Age at diagnosis also appeared to be prognostic, as patients younger than ten years had a more favorable outcome [11] .
Treatment of stage Ic tumors, where the tumor is confined to the ovaries but has ruptured or the capsule has been violated at the time of surgery, remains rather controversial. In a study of 62 patients, intraoperative rupture or violation of the tumor capsule did not negatively impact long-term outcome or recurrence, whereas if the tumor had ruptured preoperatively or malignant ascites was present, these patient would likely benefit from chemotherapy [10] . If the rupture occurred intraoperatively and there were !20 mitoses/10HPF, then adjuvant chemotherapy should be considered [9] .
After initial surgical treatment, patients require long-term follow-up and persistent surveillance with imaging and tumor markers. Recurrence has been seen with stage I JGCT up to eight years post-operatively [2] .
Interestingly, a case report published in 2009 does provide evidence of spontaneous regression of JGCT after an infant's parents refused bilateral oophorectomy. Two months after diagnosis of JGCT, the patient had normal hormone levels and this persisted over two years of follow-up [12] . Ovarian sex-cord stromal tumors (SCST), which includes JGCT as a subtype, have also been associated with familial pleuropulmonary blastoma (PPB) and the DICER1 gene mutation. The ovarian SCST may be the initial clinical presentation of DICER1 mutations within some families, so genetic testing should be considered in these patients, especially if they have any signs of leprechaunism or if they develop a PPB [13, 14] . These families should also be counseled about registering with the PPB Registry at http://www.ppbregistry.org. This is a rare case of congenital bilateral JGCT in a patient with no other genetic abnormalities. Initial surgical management was left salpingo-oophorectomy with delay of right salpingooophorectomy in hopes that the tumor would regress and allow ovary-sparing surgery in the future. Especially with bilateral pathology, an ovarian sparing operation should be performed when possible. At her second operation for small bowel obstruction, the tumor remained concerning with no residual normal ovary and right salpingo-oophorectomy was performed. She will continue to follow-up with routine imaging and tumor markers for surveillance of late recurrence.
Conclusion
Congenital bilateral JGCT is exceedingly rare. Ovary-sparing surgery should be the primary goal, particularly in infants with bilateral disease, but often this cannot be achieved. With early diagnosis and treatment, outcomes are favorable, but long-term follow-up is imperative to detect any late recurrences.
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